A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 379, Issue 3, 2009, Pages 241-251

  Matafome, P ^a   Nunes, E ^a   Louro, T ^a   Amaral, C ^a   Crisostomo J ^a   Rodrigues, L ^a   Moedas, A R ^a   Monteiro, P ^b   Cipriano, A ^b   Seica R ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Atorvastatin; Inflammation; Insulin treatment; Liver

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; GLUCOSE; ISOPHANE INSULIN; LIPID; MIXTARD 30 NOVOLET; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; GLUCOSE BLOOD LEVEL; GOTO KAKIZAKI RAT; HYPERLIPIDEMIA; INFLAMMATION; LIPID ANALYSIS; LIVER INJURY; LIVER PROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; RAT; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DRUG THERAPY, COMBINATION; FATTY LIVER; HEPTANOIC ACIDS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; LIPIDS; OXIDATIVE STRESS; PYRROLES; RATS; RATS, INBRED STRAINS;

EID: 59449088781     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-008-0363-y     Document Type: Article

References (47)

1. A Aas I Seljeflot P Torjesen L Diep P Thorsby K Birkeland 2006 Blood glucose lowering by lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes Diabetologia 49 872 880
2. V Athyros D Mikhailidis T Didangelos O Giouleme E Liberopoulos A Karagiannis 2006 Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study Curr Med Res Opin 22 873 883
3. B Bayés ML Granada R Lauzurica MC Pastor M Navarro J Bonet MA Llopis R Romero 2005 Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients Transplant Proc 37 3808 3812
4. C Bisgaier A Essenburg B Auerbach M Pape C Sekerke A Gee S Wölle R Newton 1997 Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors J Lipid Res 38 2502 2525
5. M Bradbury 2006 Lipid metabolism and liver inflammation Am J Physiol Gastrointest Liver Physiol 290 G194 G198
6. M Brownlee 2005 The pathobiology of diabetic complications Diabetes 54 1615 25
7. E Bugianesi A Gastaldelli R Gambino M Cassader S Baldi V Ponti G Pagano E Ferrannini M Rizzetto 2005 Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms Diabetologia 48 634 642
8. E Bugianesi A McCullough G Marchesini 2005 Insulin resistance Hepatology 42 987 1000
9. M Cave I Deaciuc C Mendez Z Song S Joshi-Barve S Barve C McClain 2007 Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition J Nutr Biochem 18 184 195
10. H Chen G Sullivan MJ Quon 2005 Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model Diabetes 54 1914 1925
11. C Chrysohoou C Pitsavos J Skoumas C Masoura 2006 The emerging anti-inflammatory role of HDL-cholesterol, illustrated in cardiovascular disease free population, the ATTICA Study Int J Cardiol 122 29 33
12. K Comar R Sterling 2006 Review article: drug therapy for non-alcoholic fatty liver disease Aliment Pharmacol Ther 23 207 215
13. M Davidson 2005 Reducing residual risk for patients on statin therapy: the potential role of combination therapy Am J Cardiol 96 3K 13K
14. M Ekstedt L Franzén U Mathiesen M Holmqvist G Bodemar S Kechagias 2007 Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study J Hepatol 47 135 141
15. A Federico C Trappoliere C Loguercio 2006 Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives Dig Liver Dis 38 789 801
16. T Forst A Pfützner G Lübben M Weber N Marx E Karagiannis 2007 Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and pro-insulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study Metabolism 56 491 496
17. H Fujita H Fujishima J Koshimura M Hosoba T Yoshioka T Shimotomai 2005 Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice Endoc J 52 427 433
18. E Georgescu M Georgescu 2007 Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study J Gastrointest Liver Dis 16 39 46
19. E Gómez-Domínguez JP Gisbert JA Moreno-Monteagudo L García-Buey R Moreno-Otero 2006 A pilot study of atorvastatin treatment in dyslipemic, non-alcoholic fatty liver patients Aliment Pharmacol Ther 23 1643 1647
20. P Grimsrud M Picklo T Griffin D Bernlohr 2007 Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal Mol Cell Proteomics 6 624 37
21. A Hanley K Williams A Festa L Wagenknecht R D'Agostino S Haffner 2005 Liver markers and development of the metabolic syndrome Diabetes 54 3140 3147
22. T Hernandez W Capell P Wolfe L Gerard R Eckel 2006 Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus Am J Cardiol 98 1656 1659
23. H Kaneto T Matsuoka Y Nakatani D Kawamori T Miyatsuka M Matsuhisa Y Yamasaki 2005 Oxidative stress, ER stress and the JNK pathway in type 2 diabetes J Mol Med 83 429 439
24. H Lam C Chu M Wei H Keng C Lu C Sun 2006 The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia Exp Biol Med 231 1010 1015
25. S Ludwig S Dharmalingam S Erickson-Nesmith S Ren F Zhu G Ma 2005 Impact of simvastatin on homeostatic and fibrinolytic regulators in type 2 diabetes mellitus Diabetes Res Clin Pract 70 110 118
26. K Maeda H Cao K Kono C Gorgun M Furuhashi K Uysal 2005 Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes Cell Metab 1 107 119
27. L Makowski G Hotamisligil 2005 The role of fatty acid binding protein in metabolic syndrome and atherosclerosis Curr Opin Lipidol 16 543 548
28. Maseri A (1995) In: Maseri A (ed) Ischemic heart disease. Churchill Livingstone, New York, p 713
29. W Mäuser N Perwitz B Meier M Fasshauer J Klein 2007 Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function and inhibition of glucose uptake Eur J Pharm 564 37 46
30. U Meier A Gressner 2004 Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin Clin Chem 50 1511 1525
31. B Neuschwander-Tetri 2005 Nonalcoholic steatohepatitis and the metabolic syndrome Am J Med Sci 330 326 335
32. E Nunes F Peixoto T Louro CM Sena MS Santos P Matafome PI Moreira R Seiça 2007 Soybean oil treatment impairs glucose-stimulated insulin secretion and changes fatty acid composition of normal and diabetic islets Acta Diabetol 44 121 130
33. T Ota T Takamura S Kurita N Matsuzawa Y Kita M Uno 2007 Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis Gastroenterology 132 282 293
34. R Paumelle C Blanquart O Briand O Barbier C Duhem G Woerly 2006 Acute anti-inflamatory properties of statins involve peroxissome proliferator- activated receptor-α via inhibition of the protein kinase C signalling pathway Circ Res 98 361 369
35. A Pfützner T Forst 2006 High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus Diabetes Technol Ther 8 28 36
36. A Planavila L Juan M Vásquez-Carrera 2005 Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappaB activation Biochim Biophys Acta 1687 76 83
37. K Satoh N Keimatsu M Kanda T Kasai A Takaguri F Sun K Ichihara 2005 HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats Biol Pharm Bull 28 2092 2095
38. RM Seiça KI Suzuki RM Santos LM Rosário 2004 Deficiência primária da secreção de insulina de ilhéus isolados de ratos Goto-Kakizaki, um modelo animal de diabetes tipo 2 não obesa Acta Med Port 17 42 48
39. J Sethi G Hotamisligil 1999 The role of TNFα in adipocyte metabolism Sem Cell Dev Biol 10 19 29
40. W Shang K Yasuda A Takahashi A Hamasaki M Takehiro K Nabe 2002 Effect of high dietary fat on insulin secretion in genetically diabetic Goto-Kakizaki rats Pancreas 25 393 399
41. G Shetty P Economides E Horton C Mantzoros A Veves 2004 Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes Diabetes Care 27 2450 2457
42. S Shoelson L Herrero A Naaz 2007 Obesity, inflammation, and insulin resistance Gastroenterology 132 2169 2180
43. V Wong L Stavar L Szeto K Uffelman C Wang G Fantus G Lewis 2006 Atorvastatin induces insulin sensitization in Zucker fatty rats Atherosclerosis 184 348 355
44. T Yamauchi J Kamon Y Ito A Tsuchida T Yokomizo S Kita 2003 Cloning of adiponectin receptors that mediate antidiabetic effects Nature 423 762 769
45. H Yki-Järvinen 2005 Fat in liver and insulin resistance Ann Med 37 347 356
46. M Yoneda T Iwasaki K Fujita M Inamori Y Nozaki S Maeyama 2007 Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue Alcohol Clin Exp Res 31 15S 21S
47. H Zhou X Song M Briggs B Violand E Salsgiver Y Luo 2005 Adiponectin represses gluconeogenesis independent of insulin in hepatocytes Biochem Biophys Res Commun 338 793 799